Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Board

Christopher Kaplan, currently President of Cajetan, LLC, will now be appointed to Provectus Biopharmaceuticals Strategic Advisory Board.

Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and then in US marketing. He began his international experience in Paris as the CV Marketing Director for Europe and then progressed to his last role at Bristol-Myers Squibb as Marketing and Sales Director in Rome, Italy.

Kaplan, a graduate of Columbia University, holds a Masters of Science Degree from the University of Pennsylvania, and undertook post-graduate studies at INSEAD, Fontainebleu, France. He has also completed executive education programs at Harvard, Wharton and the London Business School.

CEO of Provectus, Dr. Craig Dees, PhD, said, "Chris has a formidable resume and proven track record of success in pharmaceutical sales and marketing. His experience in international business is clearly going to be an asset to Provectus, and I expect his dedication to healthcare innovation and delivery to be equally valuable.”

"I am very pleased to be joining the Provectus Strategic Advisory Board at this exciting time in the Company's development. I am impressed with the science that stands behind PV-10 as well as its prospects for regulatory approval,” Kaplan said.

To learn more go to: www.pvct.com.